Ng Chin-Hin, Chng Wee-Joo
National University Cancer Institute, Singapore, Singapore.
F1000Res. 2017 Jul 28;6:1273. doi: 10.12688/f1000research.10736.1. eCollection 2017.
Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.
急性早幼粒细胞白血病（APML）是白血病的一种亚型，由涉及15号和17号染色体的独特相互易位引起，这导致了融合基因的产生。在过去三十年中，APML已从一种高度致命的疾病转变为一种高度可治愈的疾病。这种巨大的改善得益于全反式维甲酸新治疗策略的引入，以及最近三氧化二砷的应用。APML的革命性治疗也为一种新的癌症治疗方法——基因靶向治疗铺平了道路。在这篇综述中，我们探究了这一惊人的转变历程，并介绍了APML治疗方面的最新进展。
